Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAEST16001 in Patients With Soft Tissue Sarcoma With Positive NY-ESO-1 Expression
NCT05549921Phase 2Terminated
- Sponsor
- Sun Yat-sen University
- Start
- Jul 2022
- Primary completion
- Jul 2025
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of TAEST16001 in soft tissue sarcoma (STS), sponsored by Sun Yat-sen University. Primary endpoint: Objective Response Rate at 270 days. Started Jul 2022; status: terminated.
02
Drugs
TAEST16001
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT05549921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05549921.